{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:57:23Z","timestamp":1792803443343,"version":"4.5.0"},"reference-count":180,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005946","name":"Jackson Laboratory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005946","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cancer is the leading cause of death worldwide. Cancer immunotherapy involves reinvigorating the patient\u2019s own immune system to fight against cancer. While novel approaches like Chimeric Antigen Receptor (CAR) T cells, bispecific T cell engagers, and immune checkpoint inhibitors have shown promising efficacy, Cytokine Release Syndrome (CRS) is a serious adverse effect and remains a major concern. CRS is a phenomenon of immune hyperactivation that results in excessive cytokine secretion, and if left unchecked, it may lead to multi-organ failure and death. Here we review the pathophysiology of CRS, its occurrence and management in the context of cancer immunotherapy, and the screening approaches that can be used to assess CRS and de-risk drug discovery earlier in the clinical setting with more predictive pre-clinical data. Furthermore, the review also sheds light on the potential immunotherapeutic approaches that can be used to overcome CRS associated with T cell activation.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1190379","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T04:58:23Z","timestamp":1684990703000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":117,"title":["Cytokine release syndrome and cancer immunotherapies \u2013 historical challenges and promising futures"],"prefix":"10.3389","volume":"14","author":[{"given":"Deep","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Soper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Shopland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/00007890-199004000-00009","article-title":"In vivo cell activation following Okt3 administration. systemic cytokine release and modulation by corticosteroids","volume":"49","author":"Chatenoud","year":"1990","journal-title":"Transplantation"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nm1477","article-title":"Fatal outcome of human influenza a (H5n1) is associated with high viral load and hypercytokinemia","volume":"12","author":"de Jong","year":"2006","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137647","article-title":"SARS-CoV-2: a storm is raging","volume":"130","author":"Pedersen","year":"2020","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.04.010","article-title":"Peripheral blood grafts for T cell-replete haploidentical transplantation increase the incidence and severity of cytokine release syndrome","volume":"24","author":"Raj","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.06.010","article-title":"Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated","volume":"22","author":"Abboud","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807050","article-title":"Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature","volume":"13","author":"Tay","year":"2022","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"biomark Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001792","article-title":"Bites better than CAR T cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00557","article-title":"Immune checkpoint inhibitor-related cytokine release syndrome: analysis of who global pharmacovigilance database","volume":"11","author":"Ceschi","year":"2020","journal-title":"Front Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26642","article-title":"Severe cytokine release syndrome in a patient receiving PD-1-Directed therapy","volume":"64","author":"Rotz","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217745144","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade","volume":"25","author":"Stroud","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.5922-20","article-title":"Cytokine release syndrome induced by immune-checkpoint inhibitor therapy for non-Small-Cell lung cancer","volume":"60","author":"Yomota","year":"2021","journal-title":"Intern Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21583","article-title":"Cytokine release syndrome following blinatumomab therapy","volume":"14","author":"Ojemolon","year":"2022","journal-title":"Cureus"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222313009","article-title":"Pathogenesis and treatment of cytokine storm induced by infectious diseases","volume":"22","author":"Tang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/7137900","article-title":"Potential pathophysiological mechanisms underlying multiple organ dysfunction in cytokine release syndrome","volume":"2022","author":"Chen","year":"2022","journal-title":"Mediators Inflamm"},{"key":"B19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"biomark Res"},{"key":"B20","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V96.5.1999","article-title":"Chimeric fv-zeta or fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells","volume":"96","author":"Brocker","year":"2000","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric Tcrzeta\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2005.04.016","article-title":"A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells","volume":"12","author":"Pule","year":"2005","journal-title":"Mol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-14-0186","article-title":"Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-022-01244-0","article-title":"Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells","volume":"15","author":"Tan","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba7308","article-title":"A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci Transl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B-cell non-hodgkin\u2019s lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.231183","article-title":"CD28.OX40 Co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells","volume":"106","author":"Marika","year":"2020","journal-title":"Haematologica"},{"key":"B33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.omtm.2018.01.009","article-title":"Optimizing Epha2-CAR T cells for the adoptive immunotherapy of glioma","volume":"9","author":"Yi","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-Chimeric antigen receptors targeting b-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2013.209","article-title":"A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer","volume":"25","author":"Abate-Daga","year":"2014","journal-title":"Hum Gene Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1002\/acg2.84","article-title":"Trucks, the fourth-generation CAR T cells: current developments and clinical translation","volume":"3","author":"Chmielewski","year":"2020","journal-title":"Adv IN Cell AND Gene Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"Oncoimmunology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep"},{"key":"B40","volume-title":"ProteoBlog","author":"Funfrock","year":"2021"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071493","article-title":"Alternative CAR therapies: recent approaches in engineering chimeric antigen receptor immune cells to combat cancer","volume":"10","author":"Moreno","year":"2022","journal-title":"Biomedicines"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.302","article-title":"A compound chimeric antigen receptor strategy for targeting multiple myeloma","volume":"32","author":"Chen","year":"2018","journal-title":"Leukemia"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"B47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1158\/0008-5472.CAN-13-1365","article-title":"T Lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing","volume":"74","author":"Kudo","year":"2014","journal-title":"Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-Based inhibitory chimeric antigen receptors (Icars) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3890","article-title":"A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor","volume":"72","author":"Urbanska","year":"2012","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e1368604","DOI":"10.1080\/2162402X.2017.1368604","article-title":"Msa2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting","volume":"7","author":"Lohmueller","year":"2017","journal-title":"Oncoimmunology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \u201cSafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front Pharmacol"},{"key":"B53","volume-title":"CAR T cells: engineering patients\u2019 immune cells to treat their cancers","year":"2022"},{"key":"B54","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41392-020-00256-x","article-title":"The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma","volume":"5","author":"Wei","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","article-title":"Macrophage, the potential key mediator in CAR-T related crs","volume":"9","author":"Hao","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301523","article-title":"Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity","volume":"191","author":"van der Stegen","year":"2013","journal-title":"J Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41598-021-04296-3","article-title":"The differential effects of tumor burdens on predicting the net benefits of sscart-19 cell treatment on R\/R B-ALL patients","volume":"12","author":"Li","year":"2022","journal-title":"Sci Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for all","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.611366","article-title":"Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment","volume":"12","author":"Yan","year":"2021","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J Clin Invest"},{"key":"B65","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2015.01.011","article-title":"Targeting the tumor vasculature to enhance T cell activity","volume":"33","author":"Lanitis","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e1378843","DOI":"10.1080\/2162402X.2017.1378843","article-title":"Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model","volume":"7","author":"Bocca","year":"2017","journal-title":"Oncoimmunology"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"B69","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-018-0568-6","article-title":"Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"Astct consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.3358.3358","article-title":"Tocilizumab-refractory cytokine release syndrome (CRS) triggered by chimeric antigen receptor (CAR)-transduced T cells may have distinct cytokine profiles compared to typical CRS","volume":"128","author":"Ishii","year":"2016","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S223468","article-title":"Spotlight on tocilizumab in the treatment of CAR-T-Cell-Induced cytokine release syndrome: clinical evidence to date","volume":"16","author":"Si","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153912","article-title":"Treatment-related adverse events of chimeric antigen receptor T-cell (CAR T) in clinical trials: a systematic review and meta-analysis","volume":"13","author":"Lei","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231896","article-title":"The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells","volume":"15","author":"Futami","year":"2020","journal-title":"PloS One"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16176","article-title":"Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy","volume":"25","author":"Pan","year":"2021","journal-title":"J Cell Mol Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1739","article-title":"Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy","volume":"26","author":"Huarte","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S195294","article-title":"Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy","volume":"13","author":"Cohen","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"B82","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19865","article-title":"CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1 (+) tumor cells, and extends the survival of tumor-bearing humanized mice","volume":"8","author":"Horn","year":"2017","journal-title":"Oncotarget"},{"key":"B84","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/9.7.617","article-title":"\u2018Knobs-into-Holes\u2019 engineering of antibody CH3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.4161\/19420862.2015.989013","article-title":"Production of bispecific antibodies in \u201cKnobs-into-Holes\u201d using a cell-free expression system","volume":"7","author":"Xu","year":"2015","journal-title":"MAbs"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1220145110","article-title":"Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange","volume":"110","author":"Labrijn","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B88","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ymeth.2018.11.008","article-title":"Engineering therapeutic bispecific antibodies using crossmab technology","volume":"154","author":"Klein","year":"2019","journal-title":"Methods"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2797","article-title":"Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface","volume":"32","author":"Lewis","year":"2014","journal-title":"Nat Biotechnol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ymeth.2018.10.006","article-title":"A robust heterodimeric fc platform engineered for efficient development of bispecific antibodies of multiple formats","volume":"154","author":"Moore","year":"2019","journal-title":"Methods"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-306449","article-title":"Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma","volume":"117","author":"Moore","year":"2011","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1006\/jmbi.1999.3156","article-title":"Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics","volume":"293","author":"Kipriyanov","year":"1999","journal-title":"J Mol Biol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/CJI.0b013e318156750c","article-title":"Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class","volume":"30","author":"Brischwein","year":"2007","journal-title":"J Immunother"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.626616","article-title":"Bispecific antibodies: from research to clinical application","volume":"12","author":"Ma","year":"2021","journal-title":"Front Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov Today"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0227-0","article-title":"Bispecific antibodies and their applications","volume":"8","author":"Fan","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0666","article-title":"Mgd011, a CD19 X CD3 dual-affinity retargeting bi-specific molecule incorporating extended circulating half-life for the treatment of B-cell malignancies","volume":"23","author":"Liu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0405-4","article-title":"Blinatumomab, a bispecific T-cell engager (BiTE(\u00ae)) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal4291","article-title":"An anti-glypican 3\/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors","volume":"9","author":"Ishiguro","year":"2017","journal-title":"Sci Transl Med"},{"key":"B100","article-title":"Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors","volume":"59","author":"Gillies","year":"1999","journal-title":"Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0347-5","article-title":"T Cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol Cell Biol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2039432","article-title":"Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils","volume":"11","author":"Leclercq","year":"2022","journal-title":"Oncoimmunology"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax8861","article-title":"CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity","volume":"11","author":"Li","year":"2019","journal-title":"Sci Transl Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.623610","article-title":"Therapeutic potential of TNF\u03b1 and IL1\u03b2 blockade for CRS\/ICANS in CAR-T therapy Via ameliorating endothelial activation","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1901401","article-title":"Toxicity induced by a bispecific T cell-redirecting protein is mediated by both T cells and myeloid cells in immunocompetent mice","volume":"204","author":"Godbersen-Palmer","year":"2020","journal-title":"J Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/asheducation-2018.1.25","article-title":"No free rides: management of toxicities of novel immunotherapies in all, including financial","volume":"2018","author":"Jain","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B109","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1182\/blood-2018-99-117353","article-title":"A retrospective review of tocilizumab for the management of blinatumomab (a bispecific T cell engager)-induced cytokine release syndrome (CRS)","volume":"132","author":"Choudhry","year":"2018","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B111","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-cancerbio-070620-104325","article-title":"Targeting solid tumors with bispecific T cell engager immune therapy","volume":"6","author":"Arvedson","year":"2022","journal-title":"Annu Rev Cancer Biol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-021-01067-5","article-title":"CAR-T cells and BiTEs in solid tumors: challenges and perspectives","volume":"14","author":"Edeline","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-3725","article-title":"The PSMA-targeting half-life extended BiTE therapy AMG 160 has potent antitumor activity in preclinical models of metastatic castration-resistant prostate cancer","volume":"27","author":"Deegen","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (Bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0121","article-title":"Silencing Fc domains in T cell-engaging bispecific antibodies improves T-cell trafficking and antitumor potency","volume":"7","author":"Wang","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.68","article-title":"T-Cell ligands modulate the cytolytic activity of the CD33\/CD3 bite antibody construct, AMG 330","volume":"5","author":"Laszlo","year":"2015","journal-title":"Blood Cancer J"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0014-3","article-title":"Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance Via CD28 Co-stimulation","volume":"32","author":"Correnti","year":"2018","journal-title":"Leukemia"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-2483","article-title":"A Probody(R) T-Cell-Engaging bispecific antibody targeting egfr and CD3 inhibits colon cancer growth with limited toxicity","volume":"82","author":"Boustany","year":"2022","journal-title":"Cancer Res"},{"key":"B119","article-title":"Revitope\u2013Third-Generation T cell engager immunotherapies","author":"Clement","year":"2021","journal-title":"Biopharma Dealmakers"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2034355","article-title":"Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer","volume":"11","author":"Tapia-Galisteo","year":"2022","journal-title":"Oncoimmunology"},{"key":"B121","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor Co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat Cancer"},{"key":"B122","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113285","article-title":"The immune checkpoint PD-1 in natural killer cells: expression, function and targeting in tumour immunotherapy","volume":"12","author":"Quatrini","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B125","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4062\/biomolther.2018.201","article-title":"Analysis of the expression and regulation of PD-1 protein on the surface of myeloid-derived suppressor cells (Mdscs)","volume":"27","author":"Nam","year":"2019","journal-title":"Biomol Ther (Seoul)"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.626748","article-title":"PD-L2 is constitutively expressed in normal and malignant urothelium","volume":"11","author":"Dowell","year":"2021","journal-title":"Front Oncol"},{"key":"B127","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401572","article-title":"The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity","volume":"193","author":"Ostrand-Rosenberg","year":"2014","journal-title":"J Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-123141","article-title":"B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells","volume":"111","author":"Azuma","year":"2008","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd2712","article-title":"Revisiting the PD-1 pathway","volume":"6","author":"Patsoukis","year":"2020","journal-title":"Sci Adv"},{"key":"B131","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all us food and drug administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S105862","article-title":"PD-L1 expression in human cancers and its association with clinical outcomes","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B133","doi-asserted-by":"publisher","first-page":"e002891","DOI":"10.1136\/jitc-2021-002891","article-title":"Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer","volume":"9","author":"Negrao","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00538","article-title":"Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: checkmate 032 nivolumab 1 Mg\/Kg plus ipilimumab 3 Mg\/Kg expansion cohort results","volume":"37","author":"Sharma","year":"2019","journal-title":"J Clin Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (Checkmate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-High\/Mismatch repair-deficient metastatic colorectal cancer: the phase ii checkmate 142 study","volume":"40","author":"Lenz","year":"2022","journal-title":"J Clin Oncol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1821218116","article-title":"Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies","volume":"116","author":"Wei","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108428","article-title":"Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to ipilimumab","volume":"215","author":"Pistillo","year":"2020","journal-title":"Clin Immunol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s12967-022-03409-4","article-title":"Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review","volume":"20","author":"Kov\u00e1cs","year":"2022","journal-title":"J Trans Med"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.18632\/genesandcancer.180","article-title":"The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy","volume":"9","author":"Long","year":"2018","journal-title":"Genes Cancer"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002050","article-title":"MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis","volume":"186","author":"Hemon","year":"2011","journal-title":"J Immunol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1943180","article-title":"PD-L1\/LAG-3 bispecific antibody enhances tumor-specific immunity","volume":"10","author":"Jiang","year":"2021","journal-title":"Oncoimmunology"},{"key":"B149","unstructured":"FDA approves opdualag for unresectable or metastatic melanoma"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000703","article-title":"Nivolumab in the treatment of refractory pediatric Hodgkin lymphoma","volume":"39","author":"Foran","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1159\/000496933","article-title":"First case of cytokine release syndrome after nivolumab for gastric cancer","volume":"12","author":"Oda","year":"2019","journal-title":"Case Rep Oncol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"e19741","DOI":"10.1097\/MD.0000000000019741","article-title":"A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors","volume":"99","author":"Ohira","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1159\/000525173","article-title":"Stage 4 cytokine release syndrome caused by the first dose of nivolumab and ipilimumab combination therapy in a patient with metastatic melanoma successfully treated with methylprednisolone, tocilizumab, and etanercept","volume":"15","author":"Menakuru","year":"2022","journal-title":"Case Rep Oncol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.5.3325","article-title":"\u201cCytokine storm\u201d in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics","volume":"179","author":"Stebbings","year":"2007","journal-title":"J Immunol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2016.06.006","article-title":"Cytokine release: a workshop proceedings on the state-of-the-science, current challenges and future directions","volume":"85","author":"Grimaldi","year":"2016","journal-title":"Cytokine"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1080\/1547691X.2021.1984617","article-title":"Highly sensitive in vitro cytokine release assay incorporating high-density preculture","volume":"18","author":"Ito","year":"2021","journal-title":"J Immunotoxicol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1096\/fj.14-268144","article-title":"An autologous endothelial cell: peripheral blood mononuclear cell assay that detects cytokine storm responses to biologics","volume":"29","author":"Reed","year":"2015","journal-title":"FASEB J"},{"key":"B158","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jim.2015.04.020","article-title":"Cytokine release assays for the prediction of therapeutic mab safety in first-in man trials\u2013whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm","volume":"424","author":"Vessillier","year":"2015","journal-title":"J Immunol Methods"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2012.08.018","article-title":"A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans","volume":"60","author":"Wolf","year":"2012","journal-title":"Cytokine"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071057","article-title":"A human in vitro whole blood assay to predict the systemic cytokine response to therapeutic oligonucleotides including siRNA","volume":"8","author":"Coch","year":"2013","journal-title":"PloS One"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.04.001","article-title":"Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma","volume":"27","author":"Sommer","year":"2019","journal-title":"Mol Ther"},{"key":"B162","volume-title":"CRS studies for CAR T cell therapy","year":"2022"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00922.x","article-title":"Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells","volume":"161","author":"Eastwood","year":"2010","journal-title":"Br J Pharmacol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1111\/febs.13754","article-title":"The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account","volume":"283","author":"Hunig","year":"2016","journal-title":"FEBS J"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1007\/s00335-019-09796-2","article-title":"Humanized mouse models of immunological diseases and precision medicine","volume":"30","author":"Shultz","year":"2019","journal-title":"Mamm Genome"},{"key":"B166","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/toxsci\/kfz045","article-title":"BLT-immune humanized mice as a model for nivolumab-induced immune-mediated adverse events: comparison of the nog and nog-exl strains","volume":"169","author":"Weaver","year":"2019","journal-title":"Toxicol Sci"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149093","article-title":"TGN1412 induces lymphopenia and human cytokine release in a humanized mouse model","volume":"11","author":"Weissmuller","year":"2016","journal-title":"PloS One"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12613","article-title":"Evaluation of the ability of immune humanized mice to demonstrate CD20-specific cytotoxicity induced by ofatumumab","volume":"12","author":"Semple","year":"2019","journal-title":"Clin Transl Sci"},{"key":"B169","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.trsl.2019.04.007","article-title":"Bone marrow-Liver-Thymus (BLT) immune humanized mice as a model to predict cytokine release syndrome","volume":"210","author":"Yan","year":"2019","journal-title":"Transl Res"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2014.28","article-title":"Preclinical screening for acute toxicity of therapeutic monoclonal antibodies in a hu-SCID model","volume":"3","author":"Brady","year":"2014","journal-title":"Clin Transl Immunol"},{"key":"B171","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jim.2012.07.001","article-title":"Shaw S. a humanised mouse model of cytokine release: comparison of CD3-specific antibody fragments","volume":"384","author":"Malcolm","year":"2012","journal-title":"J Immunol Methods"},{"key":"B172","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.taap.2019.03.020","article-title":"Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse models","volume":"372","author":"Yan","year":"2019","journal-title":"Toxicol Appl Pharmacol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202001203R","article-title":"A rapid, sensitive, and reproducible in vivo pbmc humanized murine model for determining therapeutic-related cytokine release syndrome","volume":"34","author":"Ye","year":"2020","journal-title":"FASEB J"},{"key":"B174","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1158\/1538-7445.AM2023-4150","article-title":"Novel preclinical model for the evaluation of cytokine release syndrome in response to CD19xCD3 bispecific antibody in humanized mice","volume":"83","author":"Shah","year":"2023","journal-title":"Cancer Res"},{"key":"B175","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1158\/1538-7445.AM2020-3354","article-title":"Preclinical evaluation of potential cytokine release syndrome and efficacy of a BCMA-CD3 bispecific antibody for the treatment of multiple myeloma in humanized mice","volume":"80","author":"Jiao","year":"2020","journal-title":"Cancer Res"},{"key":"B176","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1158\/1538-7445.AM2020-4512","article-title":"Mouse model for in vivo evaluation of efficacy and potential cytokine release syndrome of chimeric antigen receptor (CAR) T cell therapy","volume":"80","author":"Jiao","year":"2020","journal-title":"Cancer Res"},{"key":"B177","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1158\/1538-7445.AM2023-4096","article-title":"Assessing individual variability in efficacy and toxicity of autologous and allogeneic chimeric antigen receptor T-cell immunotherapy using a PBMC-humanized mouse model","volume":"83","author":"Lee","year":"2023","journal-title":"Cancer Res"},{"key":"B178","unstructured":"A new way to study cytokine release syndrome2022"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2020-4512","article-title":"Abstract 4512: mouse model for in vivo evaluation of efficacy and potential cytokine release syndrome of chimeric antigen receptor (CAR) T cell therapy","volume":"80","author":"Jiao","year":"2020","journal-title":"Cancer Res"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103525","article-title":"CARs: beyond T cells and T cell-derived signaling domains","volume":"21","author":"Sievers","year":"2020","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1190379\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T04:58:31Z","timestamp":1684990711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1190379\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":180,"alternative-id":["10.3389\/fimmu.2023.1190379"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1190379","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"article-number":"1190379"}}